海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
15件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD (EPOCH)
- mild to moderate Alzheimer's Disease MedDRA version: 15.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Spain, Turkey, United Kingdom, United States
- 2012-10-02
Authorised
- To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD)
- Alzheimer's disease MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Austria, Belgium, Canada, Chile, China, Finland, France, Germany, Hong Kong, Iceland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Singapore, South Africa, Spain, Taiwan, United Kingdom, United States
- 2017-03-31
Authorised
- This is a study to help understand how Baricitinib compares to placebo (a tablet that does not contain any active medicine) in adults with moderate to severe atopic dermatitis, also known as atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Hungary, Israel, Japan, Korea, Republic of, Poland, Spain, Switzerland
- 2017-10-05
Authorised
- A Safety and Efficacy Study for Alzheimer's Disease (Prodromal AD)
- prodromal Alzheimer's Disease MedDRA version: 16.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Finland, France, Germany, Italy, Japan, Netherlands, New Zealand, Norway, South Africa, Spain, Switzerland, United Kingdom, United States
- 2013-09-17
Authorised
- A study to help understand how Baricitinib in Combination with Topical Corticosteroids compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, Taiwan
- 2018-09-26
Authorised
- A study to help understand how Baricitinib in Combination with Topical Corticosteroids compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Germany, Italy, Japan, Korea, Republic of, Poland, Spain, Taiwan
- 2018-08-31
Authorised
- This is a long term extention study in patients with Atopic Dermatitis, also named eczema, that helps to understand how Baricitinib works BREEZE-AD1
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Czech Republic, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Slovenia, Spain, Switzerland, Taiwan
- 2017-09-22
Authorised
- To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.
- Relapsed and/or Refractory Multiple Myeloma MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2012-04-24
Authorised
- A Study of Gantenerumab in Patients with Mild Alzheimer Disease
- MILD ALZHEIMER’S DISEASE MedDRA version: 18.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Finland, France, Germany, Guatemala, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States
- 2013-12-10
Authorised
- A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease
- Prodromal Alzheimer’s Disease MedDRA version: 20.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Turkey, United Kingdom
- 2010-08-27
